Another consideration in improving trial diversity is social and structural determinants to health that impact early screening and diagnosis of patients who are historically minoritized. A consideration is the patient's access to appropriate and quality care and ability to receive referrals for ADRD screening and treatment. A key aspect that may impact ADRD diagnosis in patients of color may also relate to discrimination, socioeconomic status, insurance status, educational level, and living environment. I often wonder if we should consider measuring health disparities in the same way that we measure other biomarkers for ADRD.
Comments
Washington University
Another consideration in improving trial diversity is social and structural determinants to health that impact early screening and diagnosis of patients who are historically minoritized. A consideration is the patient's access to appropriate and quality care and ability to receive referrals for ADRD screening and treatment. A key aspect that may impact ADRD diagnosis in patients of color may also relate to discrimination, socioeconomic status, insurance status, educational level, and living environment. I often wonder if we should consider measuring health disparities in the same way that we measure other biomarkers for ADRD.
View all comments by Joyce Balls-BerryMake a Comment
To make a comment you must login or register.